Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P28799: Variant p.Ala9Asp

Progranulin
Gene: GRN
Feedback?
Variant information Variant position: help 9 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Alanine (A) to Aspartate (D) at position 9 (A9D, p.Ala9Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and hydrophobic (A) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In UP-FTD; no significant difference in the total mRNA between cases and controls; although the mutant protein is expressed it is not secreted and appears to be trapped within an intracellular compartment. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 9 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 593 The length of the canonical sequence.
Location on the sequence: help MWTLVSWV A LTAGLVAGTRCPDGQFCPVA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         MWTLVSWVALTAGLVAGTRCPDGQFCPVA

Mouse                         MWVLMSWLAFAAGLVAGTQCPDGQFCPVA

Rat                           MWILVSWLALVARLVAGTQCPDGQFCPVA

Slime mold                    -----------------------------
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Signal peptide 1 – 17
Alternative sequence 1 – 71 MWTLVSWVALTAGLVAGTRCPDGQFCPVACCLDPGGASYSCCRPLLDKWPTTLSRHLGGPCQVDAHCSAGH -> MAITAAHGASTAVQTGDPASKDQVTTPWVPSSALIVSSNARTSPRAVLWSMAPGGAAPCPRLPAVKTGCTA. In isoform 3.



Literature citations
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin.
Mukherjee O.; Pastor P.; Cairns N.J.; Chakraverty S.; Kauwe J.S.K.; Shears S.; Behrens M.I.; Budde J.; Hinrichs A.L.; Norton J.; Levitch D.; Taylor-Reinwald L.; Gitcho M.; Tu P.-H.; Tenenholz Grinberg L.; Liscic R.M.; Armendariz J.; Morris J.C.; Goate A.M.;
Ann. Neurol. 60:314-322(2006)
Cited for: VARIANT UP-FTD ASP-9; Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia.
Mukherjee O.; Wang J.; Gitcho M.; Chakraverty S.; Taylor-Reinwald L.; Shears S.; Kauwe J.S.K.; Norton J.; Levitch D.; Bigio E.H.; Hatanpaa K.J.; White C.L.; Morris J.C.; Cairns N.J.; Goate A.;
Hum. Mutat. 29:512-521(2008)
Cited for: CHARACTERIZATION OF VARIANT UP-FTD ASP-9;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.